AstraZeneca, Daiichi’s breast cancer drug gets FDA nod as first-line treatment
The U.S. Food and Drug Administration has approved Daiichi Sankyo’s therapy in combination with Roche’s drug for the first-line treatment of patients with a type of breast cancer, the regulator said on Monday.
The drug, sold under the brand name Enhertu, co-developed by Daiichi Sankyo and AstraZeneca, originally won U.S. approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients.
The new approval allows the use of Enhertu with Roche’s Perjeta to treat adults with advanced HER2-positive breast cancer confirmed by an FDA-approved test.
